Table 1.
Demographic and clinical characteristics of severe COVID-19 patients (n = 22) treated with hydroxychloroquine and for whom bronchoalveolar lavage was performed
| Characteristic | Median (IQR) | Range |
|---|---|---|
| Age (years) | 59.5 (53–70) | 30–81 |
| BMI | 28.3 (26–31.3) | 20.7–37 |
| SAPS II | 37 (32–46) | 8–76 |
| SOFA score | 6 (3–7) | 2–14 |
| Protidaemia (g/L) D7 | 61 (59–68) | 50–77 |
| AST (UI/L) D7 | 65 (69–179) | 28–135 |
| ALT (UI/L) D7 | 99 (69–179) | 18–257 |
| Bilirubin (μmol/L) D0 | 7.6 (5.15–11.2) | 4–29 |
| CKD-EPI D7 (mL/min/1.73m2) | 97 (60.5–105.8) | 9–123 |
| Duration of invasive ventilation (days) | 19.5 (11–28) | 0–22 |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; COVID-19, coronavirus disease 2019; D0, Day 0 of hydroxychloroquine initiation, D7, Day 7 after hydroxychloroquine initiation; IQR, interquartile range; SAPS, Simplified Acute Physiology Score; SOFA, Sepsis-related Organ Failure Assessment.